Favorable responses to upadacitinib, a JAK1 inhibitor, in long COVID patients with predominant neuropsychiatric symptoms: case reports in 2 autistic patients and one typically developing patient
Abstract The long-term impact of coronavirus disease 2019 (COVID-19) has become evident over the past 3–4 years, with the recognition of post-COVID long-term sequelae, often referred to as long COVID. Neuropsychiatric symptoms are one of the hallmarks of long COVID. In severe cases, it can even pres...
Saved in:
| Main Authors: | Harumi Jyonouchi, Jeffery Kornitzer, Lee Geng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-025-04341-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight
by: Francesca Falcinelli, et al.
Published: (2025-04-01) -
Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis
by: Diego Dominguez, et al.
Published: (2025-05-01) -
Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
by: Ziyu Qi, et al.
Published: (2025-08-01) -
Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review
by: Olimpia Wiciun, et al.
Published: (2025-05-01) -
The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
by: Yu. A. Lushpaeva
Published: (2025-04-01)